Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.
CRIS · Curis Inc · Documents
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Curis, Inc. says $5.0 million of cash plus approximately $7.5 million from the October 2026 Private Placement fund operations into the first quarter of 2027. Substantial going-concern doubt remains; Curis appealed Nasdaq’s November 2, 2026 delist determination.
Curis reported a third-quarter net loss of $8.1 million, no revenue, and $5.0 million cash as of September 30, 2026; it believes financing will fund operations into the first quarter of 2027, while 2 emavusertib studies continue enrolling.
Curis reported an 86% response rate in seven BTK-naive primary CNS lymphoma patients and responses in 10 of 39 salvage-line patients. Full enrollment is expected in 2027, followed by an NDA filing in 2028.
Nasdaq notified Curis, Inc. on November 2, 2026 that common stock closed below the minimum $1.00 per share for 30 business days. A July 6, 2026 1-for-20 reverse stock split left the company ineligible for a compliance period.
Curis will ask stockholders at a virtual special meeting on November 18, 2026 to approve a reverse stock split ranging from 1-for-5 to 1-for-12, with the board determining the ratio.
Curis seeks stockholder approval at a virtual special meeting on November 18, 2026 for a reverse stock split of its common stock at a ratio from any whole number between 1-for-5 and 1-for-12, set by the Board in its discretion and subject to its authority to abandon the amendments. Holders of record on October 26, 2026 will vote, and an adjournment vote is also sought.
Curis agreed to sell 16,666,680 shares of common stock, or pre-funded warrants, together with common warrants at an effective combined price of $0.51 per share. Gross proceeds are expected to be approximately $8.5 million before placement agent fees and offering expenses. The common warrants have a $0.60 exercise price and will terminate on April 19, 2032.